Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers

Urology has been beset by several major trends that have shifted the entire paradigm for prostate cancer screening.

These stem from a backlash against overdiagnosis and overtreatment due to prostate-specific antigen (PSA)-based screening efforts and have led national societies to modify their guidelines.

More importantly, the public outcry has shifted the focus of early detection from an effort to diagnose any and all prostate cancers to an effort to diagnose clinically significant prostate cancers at an early stage.

This review provides an update on contemporary biomarkers for prostate cancer that may be used to supplement PSA-based screening approaches.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe